New mutations in TP53 gene drive resistance to p53-targeted cancer therapy

Mutations in the tumor suppressor TP53 are a common cause of cancer, making the altered protein an attractive target for therapeutics. Among them, the Y220C mutation is the ninth most frequent and it ...
ascopubs.org

The impact of TP53 mutations and use of the TP53-mutation-reactivating agent APR-246 on metastatic castrate-sensitive prostate cancer.

Efficacy and safety of darolutamide in Chinese patients with metastatic hormone-sensitive prostate cancer (mHSPC): A subpopulation analysis of the phase 3 ARASENS study. This is an ASCO Meeting ...
The American Journal of Managed Care

In Mantle Cell Lymphoma, Not all TP53 Mutations Are Created Equal

In mantle cell lymphoma (MCL), an aggressive form of B-cell non-Hodgkin lymphoma, TP53 mutations are known to affect patients’ prognosis—but questions remain. What does the heterogeneity of TP53 ...
ascopubs.org

TP53 genomic alterations including targetable TP53 Y220C mutation in clinically advanced breast cancer.

Integrating dynamic analysis of serial ctDNA testing to enhance diagnostic and prognostic assessments in patients with metastatic breast cancer.
Cure Today

Brukinsa Supported as First-Line Treatment for Patients With CLL/SLL

Brukinsa showed superior PFS and ORR compared to Rituxan in CLL/SLL patients, with a 71% risk reduction in progression or death. Brukinsa's efficacy was consistent across various risk factors, ...